[IP] Dutch pump study
Ned Tijdschr Geneeskd. 2003 Oct 11;147(41):2021-5. <A
[Article in Dutch]
de Borst JM, Berghout A.
Medisch Centrum Rijnmond-Zuid, locatie Zuider, vakgroep Interne Geneeskunde,
Groene Hilledijk 315, 3075 EA Rotterdam.
OBJECTIVE: To determine the HbA1c-values and the degree of satisfaction of
patients who had switched from multiple subcutaneous insulin injections to
continuous subcutaneous insulin infusion (CSII). DESIGN: Retrospective. METHOD:
Data were collected and evaluated from all patients with type 1 or 2 diabetes
mellitus who started treatment with CSII in the period from 1 January 1999 to
December 2001 in the Rijnmond-Zuid Medical Centre, Zuider site, Rotterdam, the
Netherlands. The data included the insulin dosage and HbA1c-percentages
before and three months after the start of CSII, and the degree of satisfaction
the patients on a scale from 1 (poor) to 10 (good). RESULTS: Of the 57
patients who started CSII, two resumed multiple daily subcutaneous injections
a few months. Of the other 55 patients, 36 (including 15 men) had type-1
diabetes, with an average age of 36.1 years, and 19 (including 8 men) had
diabetes, with an average age of 49.7 years. Poor regulation of the blood
glucose levels was the main reason (n = 40; 73%) for switching to CSII. In the
patients with type-1 diabetes, there was no significant change in the total
of insulin before and during CSII, while the mean HbA1c-level decreased from
8.2 (SD: 1.2) to 7.3% (SD: 1.0; p = 0.0005). In the 19 patients with type-2
diabetes, there was also no significant change in insulin dosage, while the
HbA1c-level decreased from 8.1 (SD: 1.0) to 7.6% (SD: 1.1; p = 0.056). All 47
interviewed patients were satisfied with the treatment. The mean score was 8.3
type-1 diabetes mellitus and 8.1 in type-2 diabetes mellitus. CONCLUSION:
Following three months on CSII, the average HbA1c-percentages were lower than
during the previous treatment with multiple subcutaneous insulin injections.
patients were satisfied with the convenience of the treatment.
PMID: 14587146 [PubMed - in process]
for HELP or to subscribe/unsubscribe, contact: